| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.6 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | ETP-46464 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.6 |
| mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | 0.04 | 0.6 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |